ArticleActa neuropathologica communications2026
Prognostic stratification of chordoid meningiomas: the role of chromosome 1p/22q Loss.
Article in Acta neuropathologica communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Chordoid is a rare WHO grade 2 meningioma subtype with unpredictable clinical behavior. This study evaluated the prognostic significance of chromosomes 1p and 22q deletions, DNA methylation-based classification, and immunohistochemical expression of ACADL, MCM2, and H3 K27me3 in 44 chordoid meningiomas to assess whether these factors can be used to improve the stratification of these tumors. Deletion of chromosome 1p was detected in 53% of cases and was significantly associated with tumor recurrence and shorter recurrence-free survival (RFS). The concurrent deletion of 1p and 22q was further correlated with poorer outcomes and remained an independent prognostic factor in the multivariate analysis. MCM2 expression was also linked to higher recurrence rates and reduced RFS, whereas DNA methylation classes and H3 K27me3 expression showed no prognostic relevance in this study. These findings support the use of 1p/22q copy number status and MCM2 immunohistochemistry for improved prognostic stratification of chordoid meningiomas, whereas DNA methylation profiling and H3 K27me3 assessment appear less informative for this subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.